Nano-X Imaging (NNOX) Stock Forecast & Price Target

Nano X Imaging is supported by a gradually improving commercial trajectory, with fourth-quarter 2025 revenue rising to $3.7M from $3.0M on the back of teleradiology growth and Nanox Health IT, while management reaffirmed a $35M full-year 2026 revenue target that signals confidence in scaling adoption. The company’s positive outlook is further strengthened by its capital-light go-to-market strategy, using established regional partners like Digital X-Ray Imaging to accelerate Nanox.ARC deployments across major health systems in Arkansas, leverage entrenched service infrastructure, and reduce the operational friction that often slows medical imaging rollouts. Fundamentally, the thesis rests on Nanox.ARC’s positioning as a lower-cost, lower-radiation alternative to traditional CT, the expanding distribution cadence that should broaden access and utilization, and the company’s multi-segment platform in which Radiology Services already provides the key revenue base, even as the $17.5M non-cash impairment underscores that execution and reimbursement remain critical risks.

Nano X Imaging is still fundamentally challenged by a business model that has not yet translated channel expansion into durable hardware monetization, as imaging system revenue was only $0.049M versus $3.1M from teleradiology, showing that the company’s key revenue engine remains services rather than scalable device sales. The widening net loss to $33.4M from $14.1M in the prior year, driven in part by an impairment tied to scaling back portions of its South Korean chip manufacturing line, highlights execution risk, capital inefficiency, and the fragility of its manufacturing strategy. Although the company had about 36 systems in deployment, expects 17 more installations through its Nanox Imaging Network, and ended with $60.0M in cash and equivalents, the reliance on partner execution, adoption timing, and regulatory/commercial success makes the $35M revenue target for 2026 highly uncertain.